M&A Deal Summary |
|
|---|---|
| Date | 2022-06-23 |
| Target | ADx NeuroSciences |
| Sector | Life Science |
| Buyer(s) | Fujirebio |
| Deal Type | Add-on Acquisition |
| Deal Value | 40M EUR |
SEARCH BY
Fujirebio focused on developing and marketing CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. It remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools. Fujirebio was formed in 1950 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| Country: Belgium M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-23 |
Plasma Services Group
Moorestown, New Jersey, United States Plasma Services Group specializes in the collection, screening, and supply of biological materials required for R&D and manufacturing in the in vitro diagnostics (IVD) and life science industries. The Group provides sera and other samples for materials of control reagents and calibrators for a wide range of diseases and offers sample collection services globally. Plasma Services Group was formed in 2004 and is based in Moorestown, New Jersey. |
Buy | - |